Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...
Motilal Oswal sees opportunities in select consumption stocks despite the sector's six-month underperformance, driven by weak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback